TAG:
blood brothers
Why DIANON Sale Alters Anatomic Path Market
By Robert Michel | From the Volume IX No. 16 – November 18, 2002 Issue
CEO SUMMARY: By acquiring DIANON Systems, LabCorp raises the level of competition for tissue specimens originating in physicians’ offices. LabCorp’s acquisition is also a validation of predictions that cancer diagnostics will be a high-growth segment of laboratory medicine. Anatomic p…
Quest & LabCorp Encounter Different Business Hurdles
By Robert Michel | From the Volume IX No. 14 – October 7, 2002 Issue
IT’S BEEN TOUGH SLEDDING in recent months for both Laboratory Corporation of America and Quest Diagnostics Incorporated. THE DARK REPORT believes there may be significance in these developments. Both national labs find themselves confronted with unexpected obstacl…
Removing Lab Players From the Chessboard
By R. Lewis Dark | From the Volume IX No. 13 – September 16, 2002 Issue
IN 1997-98, CEO Ken Freeman of Quest Diagnostics Incorporated made a keen insight about the commercial lab marketplace. At that time the three blood brothers—Laboratory Corporation of America, Quest Diagnostics, and SmithKline Beecham Clinical Laboratories…
Changes Expected in Market For Hospital Reference Testing
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: For the hospital send-out testing marketplace, 2002 has been an eventful year. First came the acquisition of American Medical Laboratories by Quest Diagnostics Incorporated. In April, Specialty Laboratories disclosed its problems with state and federal laboratory regulators. …
Read “Waiver of Charges” for What It Is: FREE!
By R. Lewis Dark | From the Volume IX No. 12 – August 26, 2002 Issue
TODAY I AM AN OLD CURMUDGEON WHO IS IN HIGH DUDGEON. What’s got my dander up is the disturbing revelation in this issue of THE DARK REPORT about the willingness by some of our industry’s biggest companies to use “free testing” as a way to protect and build market share. (See pages 2-8…
Two Blood Brothers Use “Free Testing” Strategy
By Robert Michel | From the Volume IX No. 12 – August 26, 2002 Issue
CEO SUMMARY: It’s a business strategy that Quest Diagnostics Incorporated and Laboratory Corporation of America use in selected areas where they have lost exclusive managed care contracts to regional lab competitors. In order to retain access to a physician’s fee-for-service testing b…
Will “Free Testing” Ploy Financially Affect Labs?
By Robert Michel | From the Volume IX No. 12 – August 26, 2002 Issue
CEO SUMMARY: It’s a marketing scheme which public lab companies have quietly used for years. Now there is evidence that the use of “Waiver of Charges to Managed Care Patients” (free testing) seems to be on the increase, raising new questions about how and why competitive practices a…
Commercial Lab JVs With Hospitals Are Declining In Number
By Robert Michel | From the Volume IX No. 8 – June 3, 2002 Issue
CEO SUMMARY: There are many reasons why a properly-designed and well-managed laboratory test joint venture (JV) between a commercial lab company and a hospital should succeed. But no matter how strong such concepts look on paper, the real world has proven to be a harsh environment. A hand…
Sigma-Aldrich, Ivax Diagnostics, i-STAT, Quest Diagnostics, Unilab
By Robert Michel | From the Volume IX No. 8 – June 3, 2002 Issue
SIGMA-ALDRICH SELLS ITS EIA PRODUCT LINE TO IVAX DIAGNOSTICS FOLLOWING ITS DECISION TO EXIT the clinical diagnostics market, Sigma-Aldrich, Inc. has sold its global enzyme immunoassay (EIA) product line to Ivax Diagnostics, Inc., based in Miami, Florida. Th…
More Lab Consolidation: LabCorp Buys Dynacare
By Robert Michel | From the Volume IX No. 7 – May 13, 2002 Issue
CEO SUMMARY: Recent weeks brought many rumors about an impending deal between Laboratory Corporation of America and Dynacare. That speculation was ended last week when it was disclosed that LabCorp would pay about $685 million in cash, stock and assumed debt to acquire Dynacare. The acqui…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized